Costa A, Silvestrini R, Grignolio E, Clemente C, Attili A, Testori A
Oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Cancer. 1987 Dec 1;60(11):2797-800. doi: 10.1002/1097-0142(19871201)60:11<2797::aid-cncr2820601133>3.0.co;2-b.
The 3H-thymidine labeling index (LI) was determined on 178 lesions, four of which were primary, from 129 patients with malignant melanoma. The overall analysis showed a wide variability of LI values, from 0.01% to 31.7%, with an exponential distribution and a median value of 8.0%. Similar median LI values were observed for the various metastatic sites, and no difference was found between patients who only had surgery and those who also received systemic therapy. Cell kinetics and patient age and sex were not related in terms of extent and type of nodal involvement. Conversely, a trend toward higher proliferative activity was observed in amelanotic (8.3%) than in melanotic (5.9%) lesions (P = 0.08). The follow-up study on a series of 48 Stage II patients has shown a higher probability of 2-year survival for patients with slowly proliferating tumors than for those with rapidly proliferating tumors (86.9% versus 40.4%, P = 0.054). Along with this finding, the absence of a relationship between cell kinetics and both the main host and tumor characteristics indicated that cell kinetics was a prognostic variable and could be an important tool in the evaluation of patients with metastatic melanoma.
对129例恶性黑色素瘤患者的178个病灶进行了3H-胸腺嘧啶核苷标记指数（LI）测定，其中4个为原发性病灶。总体分析显示，LI值变化范围很大，从0.01%到31.7%，呈指数分布，中位数为8.0%。不同转移部位的LI中位数相似，仅接受手术治疗的患者与同时接受全身治疗的患者之间未发现差异。就淋巴结受累的程度和类型而言，细胞动力学与患者年龄和性别无关。相反，无色素性病灶（8.3%）的增殖活性趋势高于有色素性病灶（5.9%）（P = 0.08）。对48例II期患者的随访研究表明，肿瘤增殖缓慢的患者2年生存率高于肿瘤增殖迅速的患者（86.9%对40.4%，P = 0.054）。基于这一发现，细胞动力学与主要宿主和肿瘤特征之间均无关联，这表明细胞动力学是一个预后变量，可能是评估转移性黑色素瘤患者的重要工具。
